| 摘要 |
IP No. 595410 The present invention relates to compounds methyl [(2S)-1-{ (2S)-2-[5-(10-{ 2-[(2S)-1-{ (2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl} pyrrolidin-2-yl]-1H-imidazol-5-yl} indolo[1,2-c]-[1,3]benzoxazin-3-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl} -3-methyl-1-oxobutan-2-yl]carbamate, methyl [(2S)-1-{ (2S)-2-[5-(12-fluoro-10-{ 2-[(2S)-1-{ (2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl} pyrrolidin-2-yl]-1H-imidazol-5-yl} indolo[1,2-c][1,3]benzoxazin-3-yl)-1Himidazol-2-yl]pyrrolidin-1-yl} -3-methyl-1-oxobutan-2-yl]carbamate, and methyl [(2S)-1-{ (2S)-2-[5-(10-{ 2- [(2S)-1-{ (2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl} pyrrolidin- 2-yl]-1H-imidazol-5-yl} -6-phenylindolo[1,2-c][1,3]benzoxazin-3-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl} -3-methyl-1-oxobutan-2-yl]carbamate that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. |
